載入中
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
一般交易時段
US$10.33
+US$0.04 · +0.39%
盤中時間採用ET。市場資料可能有所延遲。
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
日內區間
目前US$10.33
52週區間
目前US$10.33
盤中時間採用ET。市場資料可能有所延遲。
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
日內區間
目前US$10.33
52週區間
目前US$10.33
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 2.28億 USD | 2.3億 USD | 2.36億 USD | 2.28億 USD | 2.53億 USD |
| 銷貨成本 | 5815.7萬 USD | 6440.4萬 USD | 6268.2萬 USD | 5509.3萬 USD | 6370.1萬 USD |
| 毛利 | 1.7億 USD | 1.66億 USD | 1.73億 USD | 1.73億 USD | 1.89億 USD |
| 研究與開發 | 6206.8萬 USD | 5493.5萬 USD | 5038.2萬 USD | 5224萬 USD | 7187萬 USD |
| 銷售、一般及管理費用 | 7120.9萬 USD | 8016.3萬 USD | 8930.8萬 USD | 8997.8萬 USD | 1.16億 USD |
| 營業費用 | 1.33億 USD | 1.35億 USD | 1.4億 USD | 1.49億 USD | 1.88億 USD |
| 利息收入 | 407.8萬 USD | 472.4萬 USD | 260.5萬 USD | 81.3萬 USD | 16萬 USD |
| 利息支出 | 662.2萬 USD | 1245.2萬 USD | 1333萬 USD | 1159.2萬 USD | 1280.7萬 USD |
| 折舊和攤銷 | 1093.8萬 USD | 1152.4萬 USD | 1151.9萬 USD | 984萬 USD | 1130.5萬 USD |
| 營業利益 | 3729.9萬 USD | 3096.6萬 USD | 3264萬 USD | 2372萬 USD | 129萬 USD |
| 淨利 | 3111.1萬 USD | 3027.8萬 USD | 2159.1萬 USD | 2000 USD | −2912.6萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
